03.04.24
In a population of 602 people hospitalized with COVID-19 during the height of the pandemic, treatment with a sublingual squalene supplement significantly reduced mortality and re-hospitalization rates.
The study, published in Nature, involved the population randomized into two groups to receive either a placebo or a treatment group, the latter of which received five drops of sublingual squalene in the microemulsion form every four hours for five days in addition to standard treatment. Both groups were statistically similar in terms of demographic and clinical parameters to ensure validity. Patients were monitored for 30 days following discharge from the hospital.
After one month, 94.7% of patients in the treatment group were alive, compared to 81.4% in the control group. Additionally, only 19.3% of patients in the treatment group required re-hospitalization, compared to 46.8% in the control group.
“Recently, researchers confirmed that mortality in COVID-19 might be due to inflammation caused by the virus,” the authors wrote. “Continuous positive feedback loops between oxidative stress and pro-inflammatory signaling cause an uncontrolled hyper-inflammation state.”
While the protective mechanism of action in squalene couldn’t be determined, the authors noted that squalene may exhibit action on the NF-KB immune pathway, which appears to be a critical factor in the progression of COVID-19.
"These findings suggest that squalene administered sublingually holds promise as an effective intervention for reducing mortality and re-hospitalization rates among COVID-19 patients," said Ariati Aris, PhD, scientific affairs specialist at PhytoGaia, an ingredient supplier specializing in squalene and other plant-based nutraceuticals. "This represents a significant step forward and opportunity in our fight against the pandemic, offering a potential lifeline especially for those COVID-19 patients with severe symptoms".
“The role of squalene as an anti-inflammatory, immune-modulatory, and antioxidant drug offers promise for COVID-19 patients. PhytoGaia offers a novel combination of natural plant squalene and tocotrienol complex (STGaia) which may provide impressive synergistic heatlh benefits,” said Bryan See, vice president of PhytoGaia.
The study, published in Nature, involved the population randomized into two groups to receive either a placebo or a treatment group, the latter of which received five drops of sublingual squalene in the microemulsion form every four hours for five days in addition to standard treatment. Both groups were statistically similar in terms of demographic and clinical parameters to ensure validity. Patients were monitored for 30 days following discharge from the hospital.
After one month, 94.7% of patients in the treatment group were alive, compared to 81.4% in the control group. Additionally, only 19.3% of patients in the treatment group required re-hospitalization, compared to 46.8% in the control group.
“Recently, researchers confirmed that mortality in COVID-19 might be due to inflammation caused by the virus,” the authors wrote. “Continuous positive feedback loops between oxidative stress and pro-inflammatory signaling cause an uncontrolled hyper-inflammation state.”
While the protective mechanism of action in squalene couldn’t be determined, the authors noted that squalene may exhibit action on the NF-KB immune pathway, which appears to be a critical factor in the progression of COVID-19.
"These findings suggest that squalene administered sublingually holds promise as an effective intervention for reducing mortality and re-hospitalization rates among COVID-19 patients," said Ariati Aris, PhD, scientific affairs specialist at PhytoGaia, an ingredient supplier specializing in squalene and other plant-based nutraceuticals. "This represents a significant step forward and opportunity in our fight against the pandemic, offering a potential lifeline especially for those COVID-19 patients with severe symptoms".
“The role of squalene as an anti-inflammatory, immune-modulatory, and antioxidant drug offers promise for COVID-19 patients. PhytoGaia offers a novel combination of natural plant squalene and tocotrienol complex (STGaia) which may provide impressive synergistic heatlh benefits,” said Bryan See, vice president of PhytoGaia.
